Cargando…
A pre‐investigational new drug study of lung spheroid cell therapy for treating pulmonary fibrosis
Idiopathic pulmonary fibrosis is a lethal interstitial lung disease with unknown etiology, no cure, and few treatment options. Herein, a therapy option is presented that makes use of a heterogeneous population of lung cells, including progenitor cells and supporting cells lines, cultured in adherent...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308638/ https://www.ncbi.nlm.nih.gov/pubmed/32304182 http://dx.doi.org/10.1002/sctm.19-0167 |
_version_ | 1783549034729832448 |
---|---|
author | Cores, Jhon Dinh, Phuong‐Uyen C. Hensley, Taylor Adler, Kenneth B. Lobo, Leonard J. Cheng, Ke |
author_facet | Cores, Jhon Dinh, Phuong‐Uyen C. Hensley, Taylor Adler, Kenneth B. Lobo, Leonard J. Cheng, Ke |
author_sort | Cores, Jhon |
collection | PubMed |
description | Idiopathic pulmonary fibrosis is a lethal interstitial lung disease with unknown etiology, no cure, and few treatment options. Herein, a therapy option is presented that makes use of a heterogeneous population of lung cells, including progenitor cells and supporting cells lines, cultured in adherent and suspension conditions, the latter of which induces spontaneous spheroid formation. Within these spheroids, progenitor marker expression is augmented. The cells, called lung spheroid cells, are isolated from fibrotic lungs, expanded, and delivered in single cell suspensions into rat models of pulmonary fibrosis via tail‐vein injections. Two bleomycin‐induced fibrotic rat models are used; a syngeneic Wistar‐Kyoto rat model, treated with syngeneic cells, and a xenogeneic nude rat model, treated with human cells. The first objective was to study the differences in fibrotic progression in the two rat models after bleomycin injury. Nude rat fibrosis formed quickly and extended for 30 days with no self‐resolution. Wistar‐Kyoto rat fibrosis was more gradual and began to decrease in severity between days 14 and 30. The second goal was to find the minimum effective dose of cells that demonstrated safe and effective therapeutic value. The resultant minimum effective therapeutic dose, acquired from the nude rat model, was 3 × 10(6) human cells. Histological analysis revealed no evidence of tumorigenicity, increased local immunological activity in the lungs, or an increase in liver enzyme production. These data demonstrate the safety and efficacy of lung spheroid cells in their application as therapeutic agents for pulmonary fibrosis, as well as their potential for clinical translation. |
format | Online Article Text |
id | pubmed-7308638 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73086382020-06-24 A pre‐investigational new drug study of lung spheroid cell therapy for treating pulmonary fibrosis Cores, Jhon Dinh, Phuong‐Uyen C. Hensley, Taylor Adler, Kenneth B. Lobo, Leonard J. Cheng, Ke Stem Cells Transl Med Tissue Engineering and Regenerative Medicine Idiopathic pulmonary fibrosis is a lethal interstitial lung disease with unknown etiology, no cure, and few treatment options. Herein, a therapy option is presented that makes use of a heterogeneous population of lung cells, including progenitor cells and supporting cells lines, cultured in adherent and suspension conditions, the latter of which induces spontaneous spheroid formation. Within these spheroids, progenitor marker expression is augmented. The cells, called lung spheroid cells, are isolated from fibrotic lungs, expanded, and delivered in single cell suspensions into rat models of pulmonary fibrosis via tail‐vein injections. Two bleomycin‐induced fibrotic rat models are used; a syngeneic Wistar‐Kyoto rat model, treated with syngeneic cells, and a xenogeneic nude rat model, treated with human cells. The first objective was to study the differences in fibrotic progression in the two rat models after bleomycin injury. Nude rat fibrosis formed quickly and extended for 30 days with no self‐resolution. Wistar‐Kyoto rat fibrosis was more gradual and began to decrease in severity between days 14 and 30. The second goal was to find the minimum effective dose of cells that demonstrated safe and effective therapeutic value. The resultant minimum effective therapeutic dose, acquired from the nude rat model, was 3 × 10(6) human cells. Histological analysis revealed no evidence of tumorigenicity, increased local immunological activity in the lungs, or an increase in liver enzyme production. These data demonstrate the safety and efficacy of lung spheroid cells in their application as therapeutic agents for pulmonary fibrosis, as well as their potential for clinical translation. John Wiley & Sons, Inc. 2020-04-18 /pmc/articles/PMC7308638/ /pubmed/32304182 http://dx.doi.org/10.1002/sctm.19-0167 Text en © 2020 The Authors. stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Tissue Engineering and Regenerative Medicine Cores, Jhon Dinh, Phuong‐Uyen C. Hensley, Taylor Adler, Kenneth B. Lobo, Leonard J. Cheng, Ke A pre‐investigational new drug study of lung spheroid cell therapy for treating pulmonary fibrosis |
title | A pre‐investigational new drug study of lung spheroid cell therapy for treating pulmonary fibrosis |
title_full | A pre‐investigational new drug study of lung spheroid cell therapy for treating pulmonary fibrosis |
title_fullStr | A pre‐investigational new drug study of lung spheroid cell therapy for treating pulmonary fibrosis |
title_full_unstemmed | A pre‐investigational new drug study of lung spheroid cell therapy for treating pulmonary fibrosis |
title_short | A pre‐investigational new drug study of lung spheroid cell therapy for treating pulmonary fibrosis |
title_sort | pre‐investigational new drug study of lung spheroid cell therapy for treating pulmonary fibrosis |
topic | Tissue Engineering and Regenerative Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308638/ https://www.ncbi.nlm.nih.gov/pubmed/32304182 http://dx.doi.org/10.1002/sctm.19-0167 |
work_keys_str_mv | AT coresjhon apreinvestigationalnewdrugstudyoflungspheroidcelltherapyfortreatingpulmonaryfibrosis AT dinhphuonguyenc apreinvestigationalnewdrugstudyoflungspheroidcelltherapyfortreatingpulmonaryfibrosis AT hensleytaylor apreinvestigationalnewdrugstudyoflungspheroidcelltherapyfortreatingpulmonaryfibrosis AT adlerkennethb apreinvestigationalnewdrugstudyoflungspheroidcelltherapyfortreatingpulmonaryfibrosis AT loboleonardj apreinvestigationalnewdrugstudyoflungspheroidcelltherapyfortreatingpulmonaryfibrosis AT chengke apreinvestigationalnewdrugstudyoflungspheroidcelltherapyfortreatingpulmonaryfibrosis AT coresjhon preinvestigationalnewdrugstudyoflungspheroidcelltherapyfortreatingpulmonaryfibrosis AT dinhphuonguyenc preinvestigationalnewdrugstudyoflungspheroidcelltherapyfortreatingpulmonaryfibrosis AT hensleytaylor preinvestigationalnewdrugstudyoflungspheroidcelltherapyfortreatingpulmonaryfibrosis AT adlerkennethb preinvestigationalnewdrugstudyoflungspheroidcelltherapyfortreatingpulmonaryfibrosis AT loboleonardj preinvestigationalnewdrugstudyoflungspheroidcelltherapyfortreatingpulmonaryfibrosis AT chengke preinvestigationalnewdrugstudyoflungspheroidcelltherapyfortreatingpulmonaryfibrosis |